July 28, 2022
INNODIA iVZW has been established as a platform to access smart clinical trial expertise and data on an ability-to-pay basis. Founding members are KU Leuven, King's College London, Medical University Graz, Hannoverische Kinderheilanstalt, and Università degli Studii di Siena.
With this iVZW, INNODIA plans to:
- Bring together the leading experts in type 1 diabetes. Their network unites the brightest minds in diabetes research, ensuring cutting-edge scientific advancements and collaboration in the fight against type 1 diabetes.
- Assemble the best-in-class network of accredited clinical trial sites in Europe. With a robust network of top-tier clinical trial sites, they ensure rigorous, high-quality research that brings us closer to effective therapies for type 1 diabetes.
- Provide a gateway to top-notch professionals and research labs working on type 1 diabetes. Through INNODIA, you can gain access to a community of experts and innovative research labs dedicated to solving the challenges of type 1 diabetes.
- Provide access to a qualified community of people and families living with type 1 diabetes everywhere. Their inclusive platform connects researchers and healthcare professionals with individuals and families living with type 1 diabetes, fostering meaningful collaboration and patient-centered research.
Join INNODIA on their journey to accelerate the development of therapies that will transform the future of type 1 diabetes care.